[Click e-Stock] "Cears Technology Has Significant Upside Potential... Target Price Raised"

"Think's Sales Growth Potential Expanding Both Domestically and Internationally"

On March 16, SangSangin Securities maintained its "Buy" investment rating on SIOS Technology and raised its target price to 2.6 million won.

Ha Taegi, a researcher at SangSangin Securities, stated, "The domestic and international sales growth potential of THINK, an inpatient monitoring solution, is increasing." He explained that the reason for the inevitable acceleration in THINK’s sales from this year is the beginning of installations at the five major hospitals in Seoul. For example, THINK has been installed in certain departments at Seoul National University Hospital and Samsung Medical Center, with plans for additional installations in new wards at Asan Medical Center and Samsung Medical Center in March. The company plans to install a total of 30,000 beds this year, focusing on large domestic hospitals. Based on this, overall operating profit is projected to reach 66.9 billion won. He also predicted that Mobicare exports to the Middle East could be possible in the second half of the year.

Researcher Ha noted that although the stock price has surged in the short term, this year's stock outlook should remain aggressive. He cited the fact that THINK is making a full-scale entry into the five major hospitals in Korea, which will rapidly boost domestic sales. Even when conservatively estimating the number of target beds at 400,000 and setting the supply price at 3 million won per bed, the total domestic market amounts to 1.2 trillion won.

From the second half of 2026, exports are expected to begin in the Middle East (UAE), expanding the company's overseas market vision. He also mentioned that, in the long term, as the remote patient monitoring (RPM) market is emerging, various business opportunities derived from THINK are anticipated.

This content was produced with the assistance of AI translation services.